Central News Agency (CNA) - Bora Pharma's board of directors approved in May the acquisition of the CDMO (Contract Development and Manufacturing Organization) business spun off from US biopharmaceutical company MacroGenics for a total transaction amount of US$122.5 million (approximately NT$3.9 billion). Bora announced today that the acquisition has been completed, and it will fully target the lucrative US pharmaceutical contract manufacturing market. Bora stated that the acquisition includes the large-molecule manufacturing facility in Rockville, Maryland (hereinafter referred to as the Rockville plant) and a warehousing center in Frederick. The transaction has been officially completed as of today by Bora Biologics USA, a wholly-owned subsidiary. Concurrently, Bora has signed a CDMO service agreement with MacroGenics, continuing to provide contract manufacturing services for them. Bora emphasized that with the completion of this transaction, the Rockville plant in Maryland, the San Diego plant in California belonging to Tai-Foong Biotech, and an early-stage development site in Zhubei, Taiwan, all operate under Bora Pharma's biologics CDMO brand, Bora Biologics. In total, Bora Biologics possesses a raw material drug manufacturing capacity of 20,000 liters using single-use bioreactors (SUB). Bora will entrust Tai-Foong Biotech as the sole business development team for the Bora Biologics brand. The group will coordinate resources and focus on business development and commercial execution. With a larger production scale, more comprehensive commercial manufacturing experience, and a richer track record of regulatory inspections, Bora will accelerate the expansion of late-stage clinical and commercial projects, enhancing its international visibility. Bora Pharma Chairman and CEO, Dr. Pei-Hsiu Sheng, stated that with the expansion of Bora Biologics, Bora looks forward to establishing a reliable US-based biologics manufacturing platform for its pharmaceutical clients, cov